Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Overview

Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for provoked VTE. Purpose: To establish the safety and efficacy of low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor. Population: Outpatients with provoked VTE with at least one persistent provoking factor. Enrollment: 600 subjects Randomization: 1:1 Clinical Site Locations: 1 center (Brigham and Women's Hospital) Study Duration: 36 months; enrollment period of up to 20 months with 12-month follow-up. Primary Safety and Efficacy Outcomes: Primary Safety Outcome: International Society on Thrombosis and Haemostasis (ISTH) major bleeding at 12 months. Primary Efficacy Outcome: Symptomatic, recurrent VTE, defined as the composite of deep vein thrombosis and/or pulmonary embolism at 12 months. Secondary Efficacy Outcome: The composite of death due to cardiovascular cause, nonfatal myocardial infarction, stroke or systemic embolism, critical limb ischemia, or coronary or peripheral ischemia requiring revascularization (major adverse cardiovascular events, including major adverse limb events) at 12 months. Follow-Up: Follow-up will consist of Electronic Health Record (EHR) review at 12-months from study enrollment. Interim Analysis: An interim analysis for the primary safety and efficacy outcomes will be performed when 300 subjects have completed 12-month follow-up.

Provoked venous thromboembolism (VTE) is traditionally considered a transient acute disorder requiring a limited duration of anticoagulant therapy. Patients who suffer deep vein thrombosis (DVT) or pulmonary embolism (PE) following major surgery, major trauma, or periods of immobility are generally treated with time-limited anticoagulation for 3 months. However, provoked VTE patients have recently been recognized as a heterogeneous population comprised of those with transient provoking and persistent provoking risk factors (1). Common risk factors in provoked VTE such as obesity, immobility, atherosclerotic cardiovascular disease, heart failure, chronic lung disease, chronic kidney disease, and inflammatory disorders frequently contribute to an enduring rather than transient risk. Furthermore, epidemiological studies (8,9) and the randomized clinical trial EINSTEIN CHOICE (3) suggest that VTE is best characterized as a chronic disorder with periodic relapses. A landmark Danish National Registry analysis demonstrated that patients who suffer provoked or unprovoked VTE have an increased risk of recurrence over the ensuing 30 years and that recurrent PE causes increased mortality (10). While the rate of VTE recurrence ranges 30-50% over 10 years for unprovoked VTE (also termed idiopathic; unprovoked implies that an immediate trigger for the VTE cannot be identified), recurrent events occur in about 20% of patients over 10 years after a provoked event (provoked VTE is defined as post-operative, post-major trauma, post-hospitalization, or related to pregnancy, hormonal contraception/replacement therapy, or immobility) (11-13). Based on these data, provoked VTE patients represent a population vulnerable to VTE recurrence, especially at the transition of care from the initial (acute) treatment phase to the chronic treatment phase, at which point anticoagulation is discontinued in most of these patients. The EINSTEIN CHOICE trial recently evaluated the safety and efficacy of regimens of full- or lower-intensity anticoagulant therapy versus low-dose aspirin for secondary prevention of VTE after an initial provoked or unprovoked event (2). The EINSTEIN CHOICE Investigators randomly assigned 3396 patients with VTE to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. Prior to enrollment in EINSTEIN CHOICE, all study patients completed 6 to 12 months of anticoagulation therapy, and their providers were in equipoise regarding the need for extended anticoagulation. Approximately 60% of patients in EINSTEIN CHOICE had suffered provoked VTE. Symptomatic recurrent VTE occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, and in 50 of 1131 patients (4.4%) receiving low-dose aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval \[CI\], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P\<0.001 for both comparisons). Rates of major bleeding were similar (0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the low-dose aspirin group) (2). Data from 4,553 patients in EINSTEIN CHOICE and the EINSTEIN VTE Continued Treatment Study demonstrate that provoked VTE patients with persistent provoking factors have a reduction in recurrence with extended duration anticoagulation compared with low-dose aspirin or placebo (1.5% vs. 4.9%) (2,3). Common persistent provoking factors included immobility, obesity, heart failure, and chronic inflammatory disorders, such as Crohn's Disease and rheumatoid arthritis. Despite being highly prevalent, persistent provoking factors are rarely considered when stopping anticoagulation in patients with provoked VTE who have completed the typical 3- to 6-month duration of therapy. The 2016 American College of Chest Physicians (ACCP) Guidelines on Antithrombotic Therapy for VTE do not distinguish between transient and persistent provoking risk factors and recommend limited-duration anticoagulation for provoked events (4). However, an emerging opinion is that optimal duration of anticoagulation in provoked VTE patients should be determined based on data from the extended duration rivaroxaban trials (5). Such a strategy breaks from the tradition of dichotomizing VTE as provoked or unprovoked. Rather, persisting risk factors such as heart failure, obesity, family history of VTE, acquired or hereditary thrombophilia, and immobilization are incorporated into the decision-making process for pathways focused on secondary prevention. A suitable long-term strategy for secondary prevention has been recommended in evidence-based clinical practice guidelines for patients with unprovoked VTE (4). Extended-duration anticoagulation with warfarin or the direct oral anticoagulants (DOACs) is validated and recommended for prevention of recurrent unprovoked VTE in patients with a low-risk of bleeding (6). However, current evidence-based clinical practice guidelines are inadequate for secondary prevention in patients with provoked VTE based on several extended-duration anticoagulation trials that included patients with provoked and unprovoked VTE. In a randomized controlled trial of rivaroxaban for extended-duration secondary prevention in patients with either provoked (26%) or unprovoked (74%) DVT, recurrent VTE occurred in 8 patients (1.3%) in the rivaroxaban group compared with 42 patients (7.1%) in the placebo group (hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P\<0.001, relative risk reduction, 82%) (3). In a landmark extension trial of patients with unprovoked VTE, the AMPLIFY-EXT trial compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in 2486 patients with VTE who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the need for extended-duration anticoagulant therapy for secondary prevention (7). Symptomatic recurrent VTE or death from VTE occurred in 73 of the 829 patients (8.8%) who were receiving placebo versus 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (p\<0.001 for both comparisons). In Kaplan-Meier analysis, the apixaban 2.5 mg twice daily regimen demonstrated a major and clinically-relevant nonmajor bleeding rate similar to that of placebo. While approximately 9% of the patients in the AMPLIFY-EXT trial had transient or reversible risk factors for VTE, the provoked VTE population only accounted for approximately 200 patients and precluded a well-powered analysis. Furthermore, the intent of the AMPLIFY-EXT trial was to study unprovoked VTE (7). Finally, the HI-PRO trial is evaluating a more complex aspect of VTE secondary prevention. Rather than using the simple dichotomized view of VTE as provoked or unprovoked, HI-PRO is focusing on how the risk of recurrence in patients with persisting provoking factors may be modulated by low-dose apixaban. The foundation of this question is based on the current direction in which the field of VTE is moving (5) and supported by the more pathophysiologically-sound ISTH classification of risk factors (1). Apixaban 2.5 mg twice daily may have additional advantages for extended-duration secondary prevention of VTE compared with rivaroxaban 10 mg daily (which has U.S. FDA approval for extended-duration therapy). Apixaban is a more pharmacokinetically rational regimen, given the half-life of these two DOACs. In trials of stroke prevention of atrial fibrillation, apixaban demonstrated a relatively lower frequency of gastrointestinal bleeding compared with warfarin (14-17). Apixaban has fewer off-target side effects than rivaroxaban, which can cause severe headache (necessitating urgent head CT) and severe rash. Based on the emerging evidence that provoked VTE patients may require extended-duration anticoagulation for secondary prevention, the apixaban 2.5 mg twice daily dose could be a critical addition to our armamentarium in those at high risk for recurrence at the transition of care from the acute to the chronic treatment phase. However, this hypothesis needs to be tested in a clinical trial. The proposed study is a single-center, randomized controlled trial conducted at Brigham and Women's Hospital (BWH) to evaluate the feasibility of low-intensity apixaban (2.5 mg twice daily) in a study population exclusively comprised of provoked VTE patients with persistently provoking risk factors for VTE. The study has the following specific aims: Specific Aim #1: To compare the 12-month rate of recurrent symptomatic VTE in patients with provoked VTE and at least one persistent provoking factor who are randomized to either apixaban (2.5 mg orally twice daily) as monotherapy or placebo after completing at least 3 months of therapeutic anticoagulation and who have a low risk of bleeding. Hypothesis #1: Compared with placebo, oral apixaban (2.5 mg twice daily) will reduce the 12-month rate of symptomatic VTE in patients with provoked VTE and at least one persistent provoking factor who have completed at least 3 months of therapeutic anticoagulation and who have a low risk of bleeding. Specific Aim #2: To compare the 12-month rate of ISTH major bleeding in patients with provoked VTE and at least one persistent provoking factor who are randomized to either apixaban (2.5 mg orally twice daily) as monotherapy or placebo after completing at least 3 months of therapeutic anticoagulation and who have a low risk of bleeding. Hypothesis #2: Compared with placebo, oral apixaban (2.5 mg twice daily) will be associated with a similar rate of ISTH major bleeding at 12 months in patients with provoked VTE and at least one persistent provoking factor who are randomized to either apixaban (2.5 mg orally twice daily) as monotherapy or placebo after completing at least 3 months of therapeutic anticoagulation and who have a low risk of bleeding. Study Design 600-patient U.S.-based, single-center, randomized, double-blinded, placebo-controlled study of apixaban 2.5 mg orally twice daily for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor who have completed at least 3 months of standard therapeutic anticoagulation and who have a low risk of bleeding.